SCZ 7.2
VUi012-A
General
Cell Line |
|
| hPSCreg name | VUi012-A |
| Cite as: | VUi012-A (RRID:CVCL_ZB13) |
| Alternative name(s) |
SCZ 7.2
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
STBCi110-A (SFC116-03-01) Donor's gene variants: CFH Donor diseases: type 2 diabetes mellitus age-related macular degeneration |
| Last update | 6th October 2023 |
| User feedback | |
Provider |
|
| Generator | Vrije Universiteit Amsterdam (VU) |
External Databases |
|
| Cellosaurus | CVCL_ZB13 |
| Wikidata | Q98134636 |
| BioSamples | SAMEA114469022 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA114469023 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Please provide the contact information | anna.kahler@ki.se |
| Alternatives to consent are available? | Yes |
| Alternatives to consent | original swedish instead of english |
| Alternative consent approval number | |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Swedish Ethical Review Authority |
| Approval number | 2011-324-31 and 2012/214-32 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Swedish Ethical Review Authority |
| Approval number | 2011-324-31 and 2012/214-32 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
A connective-tissue cell of mesenchymal origin that secretes proteins and especially molecular collagen from which the extracellular fibrillar matrix of connective tissue forms.
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Vitronectin | ||||||
| Feeder cells |
No |
||||||
| Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
||||||
| O2 Concentration | 5 % | ||||||
| Medium |
TeSR™ E8™
Supplements
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
||||
| SSEA-4 |
Yes |
Morphology pictures
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
No
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.